Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
OMS103HP · 4 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| OMS103HP irrigation solution | EXPERIMENTAL | Drug |
| vehicle irrigation solution | PLACEBO_COMPARATOR | Vehicle |
| 1 | EXPERIMENTAL | OMS103 Irrigation Solution |
| 2 | PLACEBO_COMPARATOR | Balanced Salt Solution (BSS) |
| Drug | EXPERIMENTAL | - |
| Vehicle | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| OMS103HP | DRUG | Maximum of 39 liters of OMS103HP irrigation solution over a maximum of 2 hours |
| Vehicle | DRUG | Maximum of 39 liters of vehicle irrigation solution over a maximum of 2 hours |
Inclusion Criteria: * 15 - 65 years of age * In good general health with an ACL tear that occurred from 2 weeks to 18 months prior to the day of arthroscopic surgery * Undergoing primary unilateral ACL reconstruction using a medial hamstring (semitendinosus and gracilis) autograft * Able to partici...
OMS103HP is an investigational small molecule being studied for postoperative pain, anterior cruciate ligament reconstruction, and knee injuries. It is administered as an irrigation solution during knee surgery. The drug is in Phase 3 clinical development and has not been approved by the FDA.
OMS103HP is being developed by Omeros Corporation, a biopharmaceutical company traded on NASDAQ under the ticker OMER. The company has conducted clinical trials of OMS103HP in the United States and Canada for knee surgery-related conditions.
OMS103HP is in Phase 3 clinical development. It has completed multiple Phase 3 trials, including studies in patients undergoing allograft and autograft anterior cruciate ligament reconstruction. The drug is investigational and has not received FDA approval.
OMS103HP has completed several clinical trials, including NCT00226759 and NCT00226772, both Phase 3 studies in patients undergoing ACL reconstruction with allograft or autograft, respectively. Additional completed trials include NCT00245271, a safety study in ACL reconstruction, and NCT00624845, a Phase 2 study in meniscectomy.
OMS103HP is a distinct investigational drug developed by Omeros Corporation. It is a small molecule irrigation solution studied specifically for knee surgery-related pain and recovery. No alternative names for OMS103HP have been disclosed in clinical trial records.